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Abstract
Antimicrobial resistance (AMR), associated with a lack of new antibiotics, is a major threat. Some countries have been able to contain
resistance, but in most countries the numbers of antibiotic-resistant bacteria continue to increase, along with antibiotic consumption by
humans and animals. AMR is a global issue, and concerns all decision-makers worldwide. Some initiatives have been undertaken in the last
15 years, in particular by the WHO, the European Centre for Disease Prevention and Control, and the CDC, but those initiatives were
partial and poorly implemented, without coordination. Very recently, some important initiatives have been implemented by the WHO.
Since 2009, a US and European joint task force, the Trans-Atlantic Task Force on Antibiotic Resistance, has been working on common
recommendations. At a national level, some important initiatives have been implemented, in particular in European countries and in the
USA. The Chennai declaration, in India, is also a good example of a multidisciplinary and national initiative that was highly political. Finally,
several non-governmental non-proﬁt organizations are also very active, and have helped to raise awareness about the problem of AMR. In
the future, this global issue will need political involvement and strong cooperation between countries and between international agencies.
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Introduction
Antimicrobial resistance (AMR) is a very serious global public
health issue worldwide. Although some countries, such as
those in Scandinavia, have been successful in maintaining very
low numbers of antibiotic-resistant bacteria, globally the
numbers of resistant bacteria continue to increase in both
humans and animals. Few new antibiotics are under develop-
ment. The increase in resistance and lack of new treatments
are particularly acute for infections caused by Gram-negative
bacteria. Furthermore, antibiotic consumption is still high, in
people in hospitals and the community as well as in animals. As
indicated by the WHO in May 2014, AMR is one of the most
serious public health issues of our time (http://apps.who.int/
iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1).
Everyone should be concerned by this crisis, as strong and
sustained action is necessary to tackle this threat.
Why is AMR a Political Issue?
AMR is a global issue, and concerns all stakeholders in every
country, and all decision-makers worldwide. Until now, most
efforts have been targeted towards technical and local issues,
and only recently have politicians in some countries become
engaged. This is the reason for the global failure of actions by
physicians and scientists, who have been warning of this crisis
for over a decade. National and international initiatives must
be implemented now and with urgency.
What has Already Been Done?
International agencies, such as the WHO and the European
Centre for Disease Prevention and Control (ECDC), have
highlighted the fact that AMR is a global threat to human
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/1469-0691.12767
health. Non-governmental organizations (NGOs) have also
played a major role in raising awareness of the crisis of AMR. In
response, governments in a few countries have implemented
campaigns to improve antibiotic use (Table 1). The vast
majority of these strategies target AMR in humans, although
some are also aimed at veterinarians and at reducing the
prevalence of antibiotic-resistant bacteria in the environment.
International agencies
As early as the late 1990s, the WHO convened a series of
meetings and expert groups to address the growing global
threat of AMR (e.g. http://whqlibdoc.who.int/hq/1997/
WHO_EMC_ZOO_97.4.pdf?ua=1; http://whqlibdoc.who.int/
hq/1998/WHO_EMC_ZDI_98.10.pdf?ua=1). Since then, many
documents on public health strategies, technical guidelines and
prioritized recommendations for the implementation of the
WHO global strategy for containment of AMR have been
published (http://www.who.int/drugresistance/). The World
Health Assembly has also issued a series of resolutions, clearly
identifying AMR as a public health priority. AMR is considered
by the WHO to be one of the three greatest threats to human
health, and was the focus of World Health Day in 2011. In
2013, the WHO established the Strategic and Technical
Advisory Group on AMR, chaired by the UK Chief Medical
Ofﬁcer Dame Sally Davies, to review and help shape a global
strategy to tackle AMR. In May 2014, the WHO published a
report ‘Antimicrobial Resistance: Global Report on Surveil-
lance’ (http://apps.who.int/iris/bitstream/10665/112642/1/
9789241564748_eng.pdf?ua=1). In 2014, its actions have
increased, and a resolution calling upon the World Health
Assembly to adopt a resolution on combating AMR was
presented in May. The draft resolution has been prepared by
member states in a process led by Sweden, the UK, and the
USA. This draft resolution calls upon the WHO, as part of its
leadership role, to lead the development of a global action plan
for AMR. The WHO has also stated that it will establish a
WHO Global Taskforce to coordinate collaboration and offer
assistance for the development of national and regional active
programmes.
In 2001, the European Commission presented its ﬁrst
comprehensive and global strategy to ﬁght AMR, advocating a
series of 15 actions in four key areas: surveillance; prevention;
research and product development; and international cooper-
ation. This action plan was updated in 2011 (http://ec.europa.
eu/health/antimicrobial_resistance/policy/index_en.htm) [1].
The Trans-Atlantic Task Force on Antimicrobial Resistance,
TABLE 1. List of some actions in place to tackle antimicrobial resistance
Name of the organization Abbreviation and website Geographical distribution Primary approach to the problem
International agencies
World Health Organization WHO; http://www.who.int/drugresistance/ International agency Lead the development of a global action plan
European Commission http://ec.europa.eu/health/antimicrobial_
resistance/policy/index_en.htm
International agency (EU) Lead the development of a European action plan
European Centre for Disease
Prevention and Control
ECDC; http://www.ecdc.europa.eu/en/
healthtopics/antimicrobial_resistance/
EU agency Lead the development of a European action plan
TransAtlantic Task Force on
Antimicrobial Resistance
TATFAR; http://www.cdc.gov/
drugresistance/tatfar/index.html
International collaboration
between the USA and the EU
Develop a joint action plan
World Organization for Animal
Health
OIE; http://www.oie.int/en/
our-scientiﬁc-expertise/veterinary-products/
antimicrobials/
International agency Lead the development of a global action plan
Food and Agriculture Organization
of the United Nations
FAO; http://www.fao.org/ag/againfo/home/
en/news_archive/2011_04_AMR.html
International agency Lead the development of a global action plan
National initiatives/campaigns
Belgian Antibiotic Policy
Coordination Committee
BAPCOC; www.bapcoc.be/ Belgium Lead the development of a national action plan
French national plan—Ministry of
Health
http://www.plan-antibiotiques.sante.gouv.fr France Lead the development of a national action plan
Swedish Strategic Programme
against Antibiotic Resistance
STRAMA; http://en.strama.se/ Sweden Advisory body Coordinate a national action plan
UK national plan—Department of
Health
https://www.gov.uk/government/
publications/uk-5-year-antimicrobial-
resistance-strategy-2013-to-2018
UK Lead the development of a national action plan
Centers for Disease Control and
Prevention
CDC; http://www.cdc.gov/drugresistance/ USA Lead the development of a national action plan
Non-governmental non-proﬁt organizations
Alliance for the Prudent Use
of Antibiotics
APUA; http://www.tufts.edu/med/apua/ Based in the USA International actions
Dutch Working Party on Antibiotic
Policy
SWAB; http://www.swab.nl/ The Netherlands National actions
Action on Antibiotic Resistance ReAct; http://www.reactgroup.org Based in Sweden International actions
Antibiotics Smart Use programme – Thailand National actions
Global Antibiotic Resistance
Partnership
GARP; http://www.cddep.org/projects/
global_antibiotic_resistance_partnership
Based in the USA Develop policy proposals on antibiotic
resistance in low-income and middle-income
countries
World Alliance Against Antibiotic
Resistance
WAAAR; http://www.waaar.org/ Based in France International actions
Antibiotic Action http://antibiotic-action.com Based in the UK International actions
Chennai Declaration http://www.chennaideclaration.org/ India National actions
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 949–953
950 Clinical Microbiology and Infection, Volume 20 Number 10, October 2014 CMI
established in 2009, has been working on recommendations
jointly developed by the USA and EU (http://www.cdc.gov/
drugresistance/tatfar/index.html).
The ECDC, established in 2005, is an EU agency that has the
aim of strengthening Europe’s defences against infectious
diseases. One of its seven programmes is devoted to AMR and
healthcare-associated infections (http://www.ecdc.europa.eu/
en/healthtopics/antimicrobial_resistance/). Among other
actions, in 2008 the ECDC launched the European Antibiotic
Awareness Day, which has become a well-known yearly event
on 18 November [2], and has now been replicated in many
other countries, including those in North America, South
America, and Australia, often as Antibiotic Awareness Week.
For more than a decade, the World Organization for
Animal Health (OIE) has worked actively to promote the
appropriate use of antibiotics in animals. Several workshops
and meetings on AMR have been held, and the OIE has
developed a list of antimicrobial agents of veterinary impor-
tance, in parallel with the WHO list for human medicine, as
well as standards and guidelines (http://www.oie.int/en/our-sci-
entiﬁc-expertise/veterinary-products/antimicrobials/). The
Food and Agriculture Organization of the United Nations also
supports measures to curb AMR in veterinary practice (http://
www.fao.org/ag/againfo/home/en/news_archive/
2011_04_AMR.html).
AMR was raised at the World Economic Forum meeting in
Davos in 2013 and 2014 (http://reports.weforum.org/global--
risks-2013/view/risk-case-1/the-dan-
gers-of-hubris-on-human-health/), as well as at the 2013 G8
meeting of Finance Ministers in London and at G20 meetings,
showing that resistance to antibiotics has become a social
issue, bridging the gap between science and politics.
National government level
A governmental national plan to combat AMR has been in
place in France since 2001; this has been associated with a
small reduction ( 10% between 2002 and 2012) in antibiotic
use in the outpatient setting (http://www.plan-antibiotiques.
sante.gouv.fr), partly because of a decrease in the rate of
patient consultation for viral infections [3].
In the UK, two 5-year AMR strategy and action plans have
been published by the Department of Health, one in 2001, and
a new 5-year strategy produced in 2013 (https://www.gov.uk/
government/publications/uk-5-year-antimicrobial-resis-
tance-strategy-2013-to-2018). In 2001, the Standing Advisory
Committee on Antimicrobial Resistance was established; in
2007, this became the Advisory Committee on Antimicrobial
Resistance and Healthcare-Associated Infection. These com-
mittees have been providing practical and scientiﬁc advice to
the UK government on strategies to maintain the effectiveness
of antimicrobial agents in the treatment and prevention of
microbial infections in humans and animals [4]. Under the
leadership of the UK Chief Medical Ofﬁcer, there was a
presentation on AMR to the Commonwealth health ministers
in May 2014. In November 2014, the interdepartmental high-
level steering group that oversees the UK 5-year AMR strategy
will publish its ﬁrst annual report on progress, with a detailed
implementation plan for further activities. The UK will also
support the development of the WHO Global Action Plan to
be adopted in 2015.
In Belgium, an Antibiotic Policy Coordination Committee
was ofﬁcially established in 1999 by Royal Decree, and this has
been implementing national initiatives, with a signiﬁcant impact
(a 36% reduction in antibiotic prescriptions between 1999 and
2007) [5].
In Sweden, the Swedish Strategic Programme against
Antibiotic Resistance (http://en.strama.se/) is an advisory body
with the remit of assisting the Swedish Institute for Infectious
Disease Control in matters regarding antibiotic use and
containment of AMR. It also facilitates an interdisciplinary
and locally approved working model, ensuring involvement by
all relevant stakeholders, including national and local author-
ities and non-proﬁt organizations.
In the USA, the CDC has been very active in this area
(http://www.cdc.gov/drugresistance/). The US Interagency
Task Force on Antimicrobial Resistance was initiated in
1999, and brings together multiple federal agencies (including
the CDC, Food and Drug Administration, and National
Institutes of Health) to address the complex issue of AMR.
Most of the planned actions of this multifaceted strategy,
including surveillance, research, education campaigns, and new
product development, have been completed (http://www.cdc.
gov/drugresistance/src/action_plan2012.html).
Despite these activities, several authors have revealed that
the impact of these international and national campaigns is often
modest, and that further strong initiatives are needed [6–9]. In
their 2012 report ‘The evolving threat of antimicrobial resis-
tance—Options for action’, the WHO also noted that ‘Inter-
national and national actions to address AMR have shown what
can be done, often with good results, but these efforts have
usually been limited in scope and lacking real coordination’.
Non-governmental non-proﬁt organizations
To raise awareness of AMR and to stimulate stronger political
engagement in this topic, several opinion leaders have created
non-governmental non-proﬁt multi-professional organizations
(NGOs). Their common denominator was the frustration that
there had been countless discussions on how to deal with
antibiotics losing their effect, but none had been translated into
activities. Some of these organizations involve patients, and all
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have developed actions and partnerships worldwide. The
Alliance for the Prudent Use of Antibiotics (http://www.tufts.
edu/med/apua/), created in 1981 in the USA, conducts
research, education and advocacy programmes in 66 devel-
oped and developing countries to control AMR. The Dutch
Working Party on Antibiotic Policy was founded in 1996 as an
initiative of the Society of Infectious Diseases and the
professional societies of medical microbiologists and hospital
pharmacists, and performed similar activities, mostly at a
national level (http://www.swab.nl/). Action on Antibiotic
Resistance (http://www.reactgroup.org), created in 2004 in
Sweden, is also working to catalyse and initiate action on AMR
worldwide by engaging with key stakeholders such as policy-
makers, civil society and non-governmental organizations,
academia and research institutions, and international organi-
zations. Action on Antibiotic Resistance recently led an
international coalition to ﬁght AMR. In Thailand, the Anti-
biotics Smart Use programme was introduced in 2007 as an
innovative model to promote the rational use of medicines and
counteract AMR. It involves a network of local multidisciplin-
ary groups at the healthcare delivery level, and a national
network of policy-makers, academics and researchers from
agencies and universities [10]. The Global Antibiotic Resis-
tance Partnership (http://www.cddep.org/projects/global_anti-
biotic_resistance_partnership) was created in 2009 in the USA
to create a platform for developing actionable policy proposals
on antibiotic resistance in low-income and middle-income
countries. The World Alliance Against Antibiotic Resistance
(http://www.waaar.org/), created in 2011 in France, comprises
> 600 individuals from 50 different countries and > 100
academic societies or professional groups throughout the
world, including physicians, veterinarians, pharmacists, econo-
mists, and patients’ advocacy groups [11]. Its primary objective
is to raise awareness among all stakeholders regarding the
AMR threat. Antibiotic Action (http://antibiotic-action.com),
also launched in 2011, is an independent UK-led global
initiative wholly funded by an NGO, the British Society for
Antimicrobial Chemotherapy. Antibiotic Action seeks to
inform and educate all about the need for the discovery of,
research on and development of new antibiotics. It also
contributes to national and international activities, and acts as
a conduit through which all stakeholders are educated on the
importance of new ways to treat bacterial infections and the
appropriate use of current antibiotics. This has included
working with like-minded organizations nationally and inter-
nationally, as well as with politicians [12–15]. Most recently, in
India, the ‘Chennai Declaration’ of 2012 was produced by
medical societies and representatives of government bodies,
and was a call for a national Indian policy on AMR (http://www.
chennaideclaration.org/) [16].
The future: What is Still Needed?
At a national level, all policy-makers, under the auspices of
ministries of health, must set up and implement sustained
national plans for the prevention and management of AMR.
This will require the participation of many government
agencies, and cooperation between several ministries is
essential (e.g. health, agriculture, environment, education and
business). In many countries (e.g. Greece, eastern Europe, and
some in Asia), the numbers of resistant bacteria are continuing
to rise sharply, and there appears to be a lack of political
engagement in tackling this issue, perhaps because of lack of
funding. However, the involvement of all antibiotic users in
minimizing antibiotic use and engagement with all stakeholders
to increase the discovery of, research on and development of
new treatments for bacterial infections is very important, so
large, national information campaigns targeting the general
public should be implemented globally.
New antibiotics that will be made available in the next few
years must be protected, and used only if necessary, for severe
infections caused by multiresistant bacteria. The sales of the
products might be relatively modest. Therefore, it will be
important to disconnect the income for the companies from
the sale of the drugs. An increase in the cost of the new
products has also been advocated.
NGOs also have a continuing and very important role in
engaging with policy-makers and politicians, and can help to
deliver national and international action plans. Strong advocacy
statements, as shown by Dame Sally Davies, Chief Medical
Ofﬁcer for the UK, are essential if politicians and policy-mak-
ers are to be actively engaged in tackling this crisis.
Antibiotic-resistant bacteria cause infections in everyone,
and cut across all demographic groups and countries. A good
example is provided by carbapenemases. NDM was ﬁrst
reported in India, and KPC was ﬁrst reported in the USA; both
spread very quickly to many countries. Global actions at an
international level are therefore of paramount importance, and
have been called for by NGOs [9]. The leadership role of the
WHO cannot be underestimated. However, despite reporting
on the topic of AMR since 2001, until recently its action has
been minimal. It is hoped that the resolution to combat AMR
and establish a global action plan presented to the World
Health Assembly in May 2014 will stimulate the large and
international response that is required to tackle this crisis. A
preservation act ratiﬁed by the WHO, OIE, and Food and
Agriculture Organization of the United Nations, and signed by
all member states, would also be very helpful. Cooperation
between countries and between continents is essential, and an
inter-governmental task force, such as that for climate change,
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should be established; this would then oversee the implemen-
tation of essential actions such as those recommended by
advocacy groups such as the World Alliance Against Antibiotic
Resistance (http://waaar.org).
There are countries that use too many antibiotics, leading
to resistance, and others that have little access to these drugs
[8]. Equity in access to antibiotics and the impact of
over-the-counter and Internet access to antibiotics is also a
complex problem. Improvements in international surveillance
and regulatory controls over production and sales of coun-
terfeit antibiotics, outdated drugs and inadequately formulated
drugs are also needed.
The use of antibiotics as growth promoters in food animal
production is still common in many countries, including the
USA. Europe banned this usage in 2006. Conﬂicts of interest
are huge, and the pressure of the commercial sector is great,
with various reasons having been provided for not stopping
this use. The ﬁrst argument is economic. The second concerns
animal health and welfare. Solutions are difﬁcult to ﬁnd, and
the problem needs strong political cooperation to ensure that
changes to practices are made.
In conclusion, there is good scientiﬁc evidence to indicate
that minimizing the use of antibiotics in all sectors, increasing
the use of vaccination and good infection control will reduce
the numbers of antibiotic-resistant bacteria in circulation;
however, the political vision and will to implement interven-
tions that will tackle resistance have, until recently, been
lacking. National and local activities are necessary, but these
will have little chance of being effective without the
involvement and commitment of national and international
policy-makers and politicians. Finally, visionary political lead-
ership is needed to resolve this crisis, which threatens to
undermine modern-day healthcare for all patients throughout
the world.
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